US EditionAdvocacy group says court battle over psilocybin-assisted therapy is a turning point
CANADA, JUL 8 – The Federal Court found Health Canada lacked sufficient justification in denying some psilocybin therapy exemptions and ordered a new decision after ruling in June.
- Therapsil, a Canadian non-profit, won a legal battle with Health Canada after obtaining exemptions to train health-care workers using psilocybin in 2020.
- The legal fight grew from Therapsil's 2022 denied application for 93 additional exemptions, leading to a June 2025 Federal Court of Appeal ruling against the health minister's refusal without justification.
- Gilchrist, Therapsil's communications director, said the case parallels medical cannabis legalization and noted growing public and governmental recognition of psychedelics' therapeutic potential.
- In recent years, over 300 individuals have been granted special permission by Health Canada to participate in psilocybin-assisted therapy, which is being researched for applications such as end-of-life support and mental health issues like treatment-resistant depression.
- Meanwhile, Alaska’s Natural Medicine initiative launched a 2025 campaign to legalize and regulate psychedelics for adults, building on voter support and Colorado’s 2022 precedent for licensed psychedelic programs.
34 Articles
34 Articles
Marijuana Moment
Alaska Activists Submit First Signatures To Put Psychedelics Legalization Measure On 2026 Ballot
Proponents of a plan in Alaska to legalize certain psychedelics—including psilocybin, mescaline and DMT—have submitted an initial round of voter signatures as part of the campaign’s effort to put the proposed measure on 2026 state ballot. Last month the group Natural Medicine Alaska, which is behind the would-be ballot initiative, announced on social media that organizers had submitted 230 voter signatures to state officials for validation. “A h…
Winnipeg Free Press
Advocacy group says court battle over psilocybin-assisted therapy is a turning point
Breaking News, Sports, Manitoba, Canada
With the authorization just received from AIFA, the first Italian trial of psilocybin, a compound extracted from certain mushroom species with hallucinogenic properties, has begun for the treatment of depression resistant to traditional treatments.
Coverage Details
Bias Distribution
- 72% of the sources lean Left
To view factuality data please Upgrade to Premium
